Oxford Biomedica Plc

Oxford Biomedica Plc

Oxford Biomedica Plc

Overview
Date Founded

1996

Headquarters

Windrush Court,Transport Way,Oxford, Oxfordshire OX4 6LT

Type of Company

Public

Employees (Worldwide)

432

Industries

Biotechnology
Pharmaceuticals

Company Description

Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The firm also provides bioprocessing and process development services to third parties. It operates through the Platform and Product segment. The Platform segment consists of the revenue generating bioprocessing and process development activities undertaken for third parties. The Product segment includes clinical and preclinical development of in vivo and ex vivo gene and cell therapy products which are owned by the group. The company was founded by Alan J. Kingsman and Susan M. Kingsman in 1996 and is headquartered in Oxford, the United Kingdom.

Executives & Employees

Executive Director, Chief Executive Officer

Chief Financial Officer & Director

Chief Scientific Officer

Chief Technical Officer

Head, Clinical Analysis

Head, Intellectual Property & Contracts

Head-Quality

General Counsel

Chief Business Officer

Chief Medical Officer

Board of Directors

Former President, International Operations at Eli Lilly & Company

Astra USA, Inc.

Former Director & Partner at Vulpes Investment Management Ltd.

Former Partner at Deloitte LLP - United Kingdom

Executive Director, Chief Executive Officer at Oxford Biomedica Plc

Investor at Broadway Angels

Chief Financial Officer & Director at Oxford Biomedica Plc

Partner & Head of NOVO Growth at Novo Principal Investments

Paths to Oxford Biomedica Plc
Potential Connections via
Relationship Science
You
Oxford Biomedica Plc
Owners & Shareholders
Details Hidden

Vulpes Investment Management is a long-term investor which aims to generate real capital appreciation and income through concentration on a small number of compelling investment opportunities. The firm's investment focus is Agriculture and German Real Estate. For long-term capital growth, Vulpes Investment Management invests across Life Sciences, Disruptive Technologies and other Private Equity style opportunities.

Details Hidden

Talos Securities Ltd. is the Great Britain-based brokerage subsidiary of Execution Services Group Ltd., itself a subsidiary of Boursorama (XP: BRS), ultimately held by Societé Générale SA (XP: GLR) in France.Authorized by the FSA in 2002, the firm is located in London and is one of Great Britain's largest execution-only stockbroking firms. Their trading name is SELF trade UK.

Details Hidden

Charles Stanley-IM uses third party and in-house research to make investment decisions. They seek profitability, growth and value, which they determine using quantitative techniques.The firm's equity research is based on fundamental analysis, using discounted cash flow valuation models and the application of multiples. To arrive at equity research recommendations, macroeconomic conditions are also considered.The Charles Stanley Sutherlands bond pricing service is a quantitative analysis that produces model prices and yields calibrated to market data. Using either the firm's or the client's inputs, the bond pricing service produces prices, yields and spreads which are compared with actual market data.The firm invests in UK and overseas equities, British government securities, fixed-income stocks, unit trusts, investment trusts, OEICs, traded options, CFDs, ETFs and traditional and covered warrants.

Recent Transactions
Details Hidden

Oxford Biomedica Plc issued Ordinary Shares

Details Hidden

Oxford Biomedica Plc issued Ordinary Shares

Details Hidden

Oxford Biomedica Plc issued Ordinary Shares

Transaction Advisors
Auditor

Advised onOxford Biomedica Plc issued Ordinary Shares

Broker

Advised onOxford Biomedica Plc issued Ordinary Shares

Broker

Advised onOxford Biomedica Plc issued Ordinary Shares

Advisors & Consultants
Legal Advisor

Partner at Fenwick & West LLP

Clients

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With nearly 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, along with our vaccines division, Sanofi Pasteur, employs more than 11,400 professionals throughout the country. At Sanofi, we work for what really matters: health

Key Stats and Financials As of 2018
Market Capitalization
$505M
Total Enterprise Value
$499M
Earnings Per Share
$0.12
Revenue
$66.8M
Enterprise Value Sales
7.47x
TEVNet Income
66.12x
Debt TEV
0.08x
Total Equity
$34.7M
Net Profit
$7.54M
Total Debt
$41.2M
EBITDAMargin
14.86%
EBITDA
$9.92M
Enterprise Value EBITDAOperating
50.26x
Three Year Compounded Annual Growth Rate Of Revenue
61.31%
Five Year Compounded Annual Growth Rate Of Revenue
65.52%
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Oxford Biomedica Plc. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Oxford Biomedica Plc's profile does not indicate a business or promotional relationship of any kind between RelSci and Oxford Biomedica Plc.